Sonnet BioTherapeutics I... (SONN)
1.23
-0.11 (-8.21%)
At close: Apr 01, 2025, 3:59 PM
1.27
2.86%
Pre-market: Apr 02, 2025, 04:34 AM EDT
Sonnet BioTherapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 |
| Revenue | 18.63K | 147.81K | 349.94K | 483.63K | n/a | 40.61M | 30.73M | 41.43M | 41.7M | 42.4M | n/a | 17.5M | 6.88M | 1.46M | 136.3K | 684.67K | 234.06K |
| Cost of Revenue | n/a | 11.81M | 93.26K | 16.63M | 58.31K | 7.93M | 29.94M | 39.41M | 38.38M | 14.04M | n/a | n/a | 2.76M | 360.81K | 11.08K | 684.67K | 234.06K |
| Gross Profit | 18.63K | -11.67M | 256.69K | -16.15M | -58.31K | 32.68M | 791.11K | 2.03M | 3.33M | 28.36M | n/a | 17.5M | 4.12M | 1.1M | 125.22K | n/a | n/a |
| Operating Income | -11.85M | -18.79M | -29.67M | -25.09M | -24.24M | -4.71M | -3.07M | -2.52M | -2.62M | -11.49M | n/a | -5.8M | -2.87M | -714.3K | -809.89K | -444.49K | -949.99K |
| Interest Income | n/a | n/a | n/a | 15.00 | 20.68K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4.54K | 46K | n/a | n/a |
| Pretax Income | -7.44M | -18.83M | -29.72M | -24.98M | -24.27M | -4.87M | -8.07M | -7.81M | -4.15M | -14.32M | n/a | -5.96M | -3.38M | -1.09M | -1.03M | -813.7K | -2.24M |
| Net Income | -7.44M | -18.83M | -29.77M | -25.01M | -31.06M | -5.03M | -6.85M | -6.79M | -9.08M | -12.14M | n/a | -5.96M | -3.17M | -1.1M | -1.01M | -813.7K | -2.24M |
| Selling & General & Admin | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 3.86M | 4.55M | 5.95M | 7.42M | n/a | n/a | 2.62M | 1.25M | 935.11K | 2.24M | 2.27M |
| Research & Development | 5.74M | 11.81M | 21.44M | 16.63M | 9.88M | 2.2M | 154.72K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Expenses | n/a | n/a | n/a | 125.5K | n/a | 11.05M | 11.05M | 5.19M | 3.45M | 3.36M | n/a | -23.29M | n/a | n/a | n/a | -1.12M | -1.14M |
| Operating Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 3.86M | 4.55M | 5.95M | 10.78M | n/a | -23.29M | 2.62M | 1.25M | 935.11K | 1.12M | 1.14M |
| Interest Expense | n/a | n/a | n/a | n/a | 20.68K | 162.87K | 381.68K | -2.59M | -2.35M | -3.47M | n/a | n/a | -474.93K | -180.82K | 140.02K | 33.91K | 20.49K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 3.5M | n/a | 145.13K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 33.8M | 43.95M | 44.32M | 24.82M | n/a | -23.29M | 9.75M | 2.18M | 946.19K | 1.13M | 1.15M |
| Income Tax | n/a | n/a | 52.48K | 22.03K | 6.8M | 162.87K | -701.22K | -644.43K | 198.46K | -187.57K | n/a | n/a | 19.2K | 14.61K | n/a | n/a | n/a |
| Shares Outstanding (Basic) | 655.24K | 1.04M | 197.46K | 79.7K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
| Shares Outstanding (Diluted) | 655.24K | 1.04M | 197.46K | 79.7K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
| EPS (Basic) | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.5K | -42.6K | n/a | -68.28K | -1.25 | -0.47 | -175.2K | -540.7K | -1.57M |
| EPS (Diluted) | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.5K | -42.6K | n/a | -68.28K | -1.25 | -0.47 | -175.2K | -540.7K | -1.57M |
| EBITDA | -11.85M | -18.72M | -29.58M | -24.99M | -24.24M | -13.15M | -3.71M | -2.93M | 541.15K | -2.73M | n/a | -3.91M | -3.24M | -1.18M | -878.82K | -376.05K | -2.21M |
| EBIT | -11.85M | -18.79M | -29.67M | -25.09M | -24.27M | -16.7M | -5.52M | -5.22M | -1.8M | -4.43M | n/a | -4.53M | -2.9M | -913.38K | -889.9K | -387.53K | -2.22M |
| Depreciation & Amortization | n/a | 75.75K | 93.26K | 95.16K | 58.31K | 3.54M | 1.82M | 2.28M | 2.34M | 2.36M | n/a | n/a | 383.45K | 87.62K | 11.08K | 11.48K | 11.2K |